Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : GP2411
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Recipient : Sandoz B2B
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 04, 2019
Lead Product(s) : GP2411
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Recipient : Sandoz B2B
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Adalimumab
Therapeutic Area : Immunology
Study Phase : Phase III
Recipient : Sandoz B2B
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
April 20, 2016
Lead Product(s) : Adalimumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Recipient : Sandoz B2B
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rituximab
Therapeutic Area : Immunology
Study Phase : Phase III
Recipient : Sandoz B2B
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
August 04, 2015
Lead Product(s) : Rituximab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Recipient : Sandoz B2B
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Adalimumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Recipient : Sandoz B2B
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
December 19, 2013
Lead Product(s) : Adalimumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Recipient : Sandoz B2B
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etanercept
Therapeutic Area : Dermatology
Study Phase : Phase III
Recipient : Sandoz B2B
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 03, 2013
Lead Product(s) : Etanercept
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Recipient : Sandoz B2B
Deal Size : Inapplicable
Deal Type : Inapplicable